BeiGene Ltd. Company Name:
BGNE Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
Trial met primary endpoint of non-inferior overall survival versus sorafenib Results mark eighth positive Phase 3 trial readout for tislelizumab across multiple cancer types and lines of therapy Data to be submitted for presentation at upcoming medical conference ...
Recorded product revenue of $304.5 million for the second quarter, representing a 120% increase from $138.6 million in the prior year period BRUKINSA product revenue increased 203% globally versus the second quarter of 2021, and 23% sequentially compared to the first qua...
FDA Defers Action on BLA Until Required Inspections Can Be Completed Due to COVID Travel Restrictions, Inspections Could Not Be Completed During Review Period BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on develop...